Scribe Therapeutics (SCTX) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($329.0 million vs $278.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCTX | SRZN |
|---|---|---|
| Share price | $17.38 | $23.71 |
| Market cap | $329.03M | $278.68M |
| 1-day change | -1.08% | -5.71% |
| YTD return | — | +11.26% |
| 1-year return | — | +82.87% |
| 5-year return | — | -73.48% |
| EPS (TTM) | $-3.84 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.60 | $37.83 |
| 52-week low | $13.50 | $11.39 |
| Distance from 52-week high | -56.11% | -37.32% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +227.96% | +104.13% |
| Average volume | 357.50K | 475.02K |
| Shares outstanding | 18.93M | 11.75M |
| Employees | 82 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
SCTX vs SRZN FAQ
Which is bigger, Scribe Therapeutics or Surrozen?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $329.03M compared with $278.68M for Surrozen (SRZN).
Are Scribe Therapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.